目的 将Gynemesh聚丙烯网片和Mersilene带植入固定于大鼠腹壁建立动物模型,分别于植入后30 d和植入后90 d进行力学实验和腹壁组织HE染色,评价两种网片的生物力学特性和组织相容性。方法 将Gynemesh网片和Mersilene带裁剪后使用W6977M聚酯不可吸收缝合线和V-Loc可吸收缝合线植入同一只雌性成年大鼠腹壁(n=10)。根据实验时间不同将大鼠随机分为30 d组和90 d组(n=5),在不同时间点进行力学实验,测试网片从腹壁撕脱的极限载荷,实验后取网片周围组织进行HE染色,对组织的炎症反应、新生血管形成、成纤维细胞增殖情况进行评分,比较不同网片的组织相容性。结果 (1)30 d组中,Gynemesh+6977组的极限载荷为(14.96±2.22) N;Gynemesh+V-Loc组为(12.73±1.11) N;Mersilene+6977组为(10.65±0.91)N;Mersilene+V-Loc组为(8.70±1.18)N。除Gynemesh+6977组与Gynemesh+V-Loc组的极限载荷差异无统计学意义(P=0.12)外,其余各组间比较差异均有统计学意义(P <0.05);(2)90 d组中,Gynemesh+6977组的极限载荷为(18.97±0.59)N;Gynemesh+V-Loc组为(18.18±0.54)N;Mersilene+6977组为(13.87±0.67)N;Mersilene+V-Loc组为(10.41±0.73)N,Gynemesh+6977组与Gynemesh+V-Loc组的极限载荷差异无统计学意义(P=0.06),其余各组间比较差异均有统计学意义(P <0.05);(3)各组90 d的极限载荷均> 30 d组,且各组间比较差异均有统计学意义(P <0.05);(4)30 d组中Gynemesh网片比Mersilene带炎症反应低(2.0±0.69 vs. 3.10±0.71,P <0.05),新生血管和成纤维细胞增殖差异无统计学意义(2.37±0.61 vs. 2.40±0.62,P=0.84;2.43±0.73 vs. 2.63±0.67,P=0.27)。90 d组中Gynemesh网片与Mersilene带相比炎症反应评分低(1.10±0.66 vs. 2.00±0.74,P <0.05),成纤维细胞增殖更少(2.87±0.68 vs. 3.27±0.67,P <0.05),新生血管增殖无明显差异(2.20±0.55 vs. 2.13±0.68,P=0.68);(5)两种网片30 d组的炎症反应均高于90 d组(Gynemesh组2.0±0.69 vs. 1.10±0.66,P <0.05;Mersilene组3.13±0.73 vs.2.0±0.74,P <0.05),成纤维细胞增殖程度更低(Gynemesh组2.43±0.73 vs. 2.87±0.68,P <0.05;Mersilene组2.63±0.67 vs. 3.27±0.69,P <0.05),新生血管的增殖无统计学意义(Gynemesh组2.53±0.74 vs. 2.47±0.74,P=0.81;Mersilene组2.40±0.62 vs. 2.13±0.68,P=0.12)。结论 Gynemesh聚丙烯网片与Mersilene带相比,具有更强的抗张力强度和更好的生物相容性。
目的探讨基于乳腺X线摄影及动态增强磁共振成像(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)的机器学习模型预测乳腺癌患者新辅助治疗(neoadjuvant therapy,NAT)后病理完全缓解(pathological complete response,pCR...
详细信息
目的探讨基于乳腺X线摄影及动态增强磁共振成像(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)的机器学习模型预测乳腺癌患者新辅助治疗(neoadjuvant therapy,NAT)后病理完全缓解(pathological complete response,pCR)的价值。方法回顾性分析2016年8月至2023年7月于青岛大学附属医院(机构1)及烟台毓璜顶医院(机构2)接受NAT后行手术的396例乳腺癌患者资料,来自机构1的320例患者按7∶3比例随机分为训练集和验证集,来自机构2的76例患者作为独立的外部验证集。对患者NAT前乳腺X线摄影及DCE-MRI图像进行感兴趣区域(region of interest,ROI)勾画、特征提取、特征筛选,使用支持向量机(support vector machine,SVM)机器学习算法构建影像组学模型。对临床特征进行单因素-多因素逻辑回归分析,保留具有统计学意义的临床独立预测因子并构建临床模型。将联合影像组学模型与临床独立预测因子使用SVM机器学习算法联合构建综合模型。采用受试者工作特征(receiver operating characteristic,ROC)曲线的曲线下面积(area under the curves,AUC)、准确性、敏感性、特异性和F1-score评价模型的性能,绘制校准曲线评价模型的拟合优度,采用决策曲线分析(decision curve analysis,DCA)评估模型的临床应用价值。结果联合影像组学模型预测性能高于临床模型、乳腺X线摄影影像组学模型和MRI影像组学模型,其在训练集、验证集和外部验证集AUC分别为0.899、0.850及0.765。综合模型预测性能最佳,其在训练集、验证集和外部验证集AUC分别为0.918、0.856、0.795,且该模型具有良好的校准能力和临床收益。Delong检验示临床模型与综合模型的AUC的差异有统计学意义(P<0.05)。结论基于乳腺X线摄影及DCE-MRI的机器学习模型可以预测乳腺癌患者NAT后pCR,且具有较高的预测性能。
目的:回顾性分析1例有多年他莫昔芬服用史乳腺癌患者的子宫内膜癌肉瘤典型病例,并结合文献复习他莫昔芬与子宫内膜癌的关系、子宫内膜癌肉瘤的治疗。方法:以病例报告的方式,结合文献复习,综合认识子宫内膜癌肉瘤的诊疗,分析他莫昔芬治疗史与子宫内膜癌的关系与管理,以降低乳腺癌他莫昔芬治疗患者的子宫内膜癌的发生率。结果:多年他莫昔芬服用史会明显增加子宫内膜癌的患病率,子宫癌肉瘤应注重个体化治疗。结论:应该注重他莫昔芬服用患者的妇科管理,同时子宫内膜癌肉瘤预后差,应重视对子宫内膜癌肉瘤患者的个体化治疗及分子检测的风险分层。Objective: Retrospective analysis of a typical case of endometrial carcinosarcoma in a breast cancer patient with a history of tamoxifen administration for many years. The study also reviewed the literature to explore the relationship between tamoxifen and endometrial cancer, as well as the treatment strategies for endometrial carcinosarcoma. Methods: Through a case report approach, combined with a review of the literature, this study provides a comprehensive understanding of the diagnosis and treatment of endometrial carcinosarcoma. It analyzes the relationship between tamoxifen treatment history and endometrial cancer, as well as its management, with the aim of reducing the incidence of endometrial cancer in breast cancer patients undergoing tamoxifen therapy. Results: A history of tamoxifen administration for many years significantly increases the prevalence of endometrial cancer, and endometrial carcinosarcoma should be focused on individualized treatment. Conclusion: Gynecologic management of tamoxifen-taking patients should be emphasized, as well as the poor prognosis of endometrial carcinosarcoma, and individualized treatment and risk stratification by molecular testing should be emphasized for patients with endometrial.
通过分析卵巢癌肉瘤的临床表现、体征、临床资料、诊疗过程及生存结局,结合国内外文献,总结最新诊疗方法,进而提升对该疾病的认识。本文回顾性分析青岛大学附属医院收治的5例卵巢癌肉瘤患者的临床表现以及诊断与治疗经验,并对相关文献进行回顾总结。所有患者均未出现特定症状,且糖类抗原125 (CA125)和人附睾蛋白4 (HE4)水平均升高。影像学检查显示4例患者为单侧卵巢肿瘤,1例患者累及双侧卵巢。增强CT扫描显示囊实性肿块,实性部分明显增强。5例患者均接受手术治疗,术后行紫杉醇和铂类化疗。3例患者没有复发或转移,1例患者复发后行维持化疗,1例患者死于复发和转移。By analyzing the clinical manifestations, signs, clinical data, diagnosis and treatment process, and survival outcomes of ovarian carcinosarcoma, combined with domestic and foreign literature, the latest diagnosis and treatment methods are summarized to enhance the understanding of this disease. This article retrospectively analyzes the clinical manifestations, diagnosis, and treatment experience of 5 patients with ovarian carcinosarcoma admitted to the Affiliated Hospital of Qingdao University, and reviews and summarizes related literature. All patients did not exhibit specific symptoms, and the levels of carbohydrate antigen 125 (CA125) and human epididymal protein 4 (HE4) were elevated. Imaging examinations showed that 4 patients had unilateral ovarian tumors, and 1 patient involved both ovaries. Enhanced CT scan shows a cystic solid mass with significant enhancement in the solid part. All 5 patients underwent surgical treatment, followed by paclitaxel and platinum-based chemotherapy. Three patients did not experience recurrence or metastasis, one patient underwent maintenance chemotherapy after recurrence, and one patient died from recurrence and metastasis.
目的:调查HER-2阴性乳腺癌患者中,不同的HER-2表达水平对新辅助化疗疗效的影响以及与患者临床病理特征的关系。方法:采集青岛大学附属医院乳腺病诊疗中心于2017年1月~2024年1月在我院确诊乳腺癌并接受新辅助化疗的HER-2阴性乳腺癌患者共164例。将HER-2阴性乳腺癌分为HER-2(0)和HER-2 low两组,分析其临床病理学特征及其与新辅助化疗疗效存在的联系。结果:164例HER-2阴性乳腺癌患者中,总pCR (病理完全缓解)率达到17.1%。HER-2 low乳腺癌患者的pCR率为11.5%,低于HER-2(0)乳腺癌患者的33.3%,其差异有统计学意义(P = 0.001)。同时还发现组织学分级、雌激素受体(ER)和孕激素受体(PR)的状态以及ki-67水平均可能与新辅助化疗疗效相关(P Objective: To investigate the effect of different HER-2 expression levels on the efficacy of neoadjuvant chemotherapy and the relationship with clinicopathological features of patients with HER-2 negative breast cancer. Methods: A total of 164 patients with HER-2 negative breast cancer who were diagnosed with breast cancer and received neoadjuvant chemotherapy in the Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qingdao University from January 2017 to January 2024 were collected. Her-2 negative breast cancer was divided into two groups, HER-2(0) and HER-2 low, and the clinicopathological features of HER-2 negative breast cancer and its relationship with the efficacy of neoadjuvant chemotherapy were analyzed. Results: In 164 patients with HER-2 negative breast cancer, the total pCR rate reached 17.1%. The pCR rate in patients with HER-2 low breast cancer was 11.5%, lower than 33.3% in patients with HER-2(0) breast cancer, and the difference was statistically significant (P = 0.001). It was also found that the status of estrogen receptor (ER) and progesterone receptor (PR) and ki-67 level may be related to the efficacy of neoadjuvant chemotherapy (P < 0.05). Logistic regression analysis showed that histological grade (OR 3.807, 95%CI 1.347~10.758, P = 0.012) and HER-2 expression status (OR 0.380, 95%CI 0.146~0.998, P = 0.047) could independently predict pCR. This conclusion can be used for neoadjuvant chemotherapy for HER-2 negative breast cancer. Conclusion: The difference of HER-2 expression status can significantly affect the efficacy of neoadjuvant chemotherapy for HER-2 negative breast
观察性研究发现,在2019冠状病毒大流行期间,女性月经不调、异常子宫出血的发病率较前增加,但没有研究证明两者之间存在因果关系。孟德尔随机化分析可以使用独立于混杂因素的遗传变异来获得因果关系的估计。我们旨在通过MR分析探讨COVID-19感染与异常子宫出血及月经不规则之间的因果关系。采用逆方差加权法(IVW)进行主要分析,并进行敏感性分析和多变量MR分析。结果发现,不同疾病程度的COVID-19患者与子宫内膜息肉存在因果关系,感染、患有严重的呼吸道疾病、住院患者的p值分别为0.0376、0.0298、0.00281,当COVID-19病毒感染进展到严重呼吸道疾病和住院阶段时,月经大出血的风险增大,p值分别为0.0432和0.0338。当接受MR-Egger回归法作为结果时,感染新冠肺炎病毒与宫颈息肉之间存在因果关系(p = 0.0490),因新冠肺炎住院的患者得子宫内膜恶性肿瘤的风险增大(p = 0.0310)。我们进一步研究了COVID-19与可能导致月经不规则的激素之间的关系,发现COVID-19可以影响宿主雌二醇和前列腺素E2的表达(COVID-19感染与前列腺素E2 p = 0.011;COVID-19感染患有严重呼吸道疾病病例与雌二醇p = 0.005;COVID-19感染住院病例与雌二醇p = 0.027)。综上所述,不同程度的新冠肺炎感染增加了女性月经大出血、子宫息肉甚至子宫内膜恶性肿瘤的风险,新冠肺炎感染同样会导致女性雌二醇及前列腺素E2水平降低,这可能进一步影响女性月经。Observational studies have identified a rise in the incidence of irregular menstruation and abnormal uterine bleeding among women during the COVID-19 pandemic. However, no studies have established a causal link between the two. Mendelian randomization analysis leverages genetic variation, which is independent of confounding factors, to estimate causality. Our aim was to explore the causal relationship between COVID-19 infection and abnormal uterine bleeding as well as irregular menstruation using MR analysis. The main analysis employed the variance inverse weighting method (IVW). Sensitivity analysis and multivariate MR analysis were also conducted. The results indicated a causal relationship between patients with varying disease severity and endometrial polyps, with p-values for patients with infection, severe respiratory disease, and hospitalization being 0.0376, 0.0298, and 0.00281, respectively. As COVID-19 virus infection progressed to severe respiratory disease and hospitalization stages, the risk of heavy menstrual bleeding increased, with p-values of 0.0432 and 0.0338, respectively. When the MR-Egger regression method was considered, there was a causal relationship between COVID-19 virus infection and cervical polyps (p = 0.0490), and the risk of endometrial malignancies in hospitalized patients due to COVID-19 also
目的:探讨炎症相关指标在高增殖活性胃肠神经内分泌肿瘤预后中的临床意义,为其患者的预后提供参考依据。方法:回顾性分析青岛大学附属医院2017~2022年48例高增殖活性胃肠神经内分泌肿瘤患者的临床资料,采用Cox回归模型进行单因素及多因素分析,Kaplan‑Meier方法进行生存分析。结果:单因素Cox回归模型显示高血压病史、肝转移、NLR、GLR是预后的影响因素(P Objective: This study aims to explore the clinical significance of inflammation-related biomarkers in predicting the prognosis of high-proliferative gastrointestinal neuroendocrine neoplasms (GI-NENs), thereby providing a reference for patient management. Methods: A retrospective analysis was conducted on the clinical data of 48 patients diagnosed with high-proliferative GI-NENs at the Affiliated Hospital of Qingdao University between 2017 and 2022. Univariate and multivariate Cox regression models were employed to identify prognostic factors, while Kaplan-Meier survival analysis was used to evaluate survival outcomes. Results: The univariate Cox regression analysis revealed that hypertension history, liver metastasis, neutrophil-to-lymphocyte ratio (NLR), and glycoprotein acetylation ratio (GLR) were significant predictors of prognosis (P < 0.05). Multivariate Cox regression analysis further indicated that NLR and liver metastasis were independent risk factors for poor prognosis (P < 0.05). Kaplan-Meier survival curves demonstrated that patients with elevated NLR and GLR had significantly shorter survival times. Conclusion: Both NLR and GLR serve as valuable indicators for predicting the prognosis of patients with high-proliferative GI-NENs.
暂无评论